Long-Term Safety Of PF-00547659 In Ulcerative Colitis

NCT ID: NCT01771809

Last Updated: 2021-06-03

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE2

Total Enrollment

330 participants

Study Classification

INTERVENTIONAL

Study Start Date

2013-03-18

Study Completion Date

2017-12-13

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Subjects with Ulcerative Colitis who have completed an induction study with PF-00547659 will receive an additional 144 weeks of open-label treatment to evaluate the long-term safety of the drug.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Ulcerative Colitis

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

SHP647 75 mg

Participants will receive 75 milligrams (mg) of SHP647 subcutaneous (SC) injection every 4 weeks for 72 weeks in the anterolateral right/left thigh or the deltoid area or the abdomen. During the first 72 weeks, a one time dose escalation to 225 mg of SHP647 SC injection every 4 weeks is allowed after 8 weeks of the study for participants who experience clinical deterioration or unacceptably low level of response to the investigational product. The decision to escalate will be guided by the response and relapse criteria tempered by clinical judgment. Following the first 72 weeks, participants will receive 75 mg of SHP647 SC injection every 4 weeks for an additional 72 weeks in the anterolateral right/left thigh or the deltoid area or the abdomen.

Group Type EXPERIMENTAL

75mg SHP647 (PF-00547659)

Intervention Type DRUG

75 mg sterile liquid injected subcutaneously every 4 weeks.

SHP647 225 mg

Participants will receive 225 mg of SHP647 SC injection every 4 weeks for 72 weeks followed by 75 mg of SHP647 SC injection every 4 weeks for an additional 72 weeks in the anterolateral right/left thigh or the deltoid area or the abdomen.

Group Type EXPERIMENTAL

225mg SHP647 (PF-00547659)

Intervention Type DRUG

225 mg sterile liquid injected subcutaneously every 4 weeks.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

75mg SHP647 (PF-00547659)

75 mg sterile liquid injected subcutaneously every 4 weeks.

Intervention Type DRUG

225mg SHP647 (PF-00547659)

225 mg sterile liquid injected subcutaneously every 4 weeks.

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Subjects between 18 and 66 years of age.
* Subjects previously enrolled in study A7281009 (NCT01620255) who have completed the 84 day (12 week) induction period.

Exclusion Criteria

* Subjects that have completed Day 84 (Week 12) of study A7281009 but have experienced serious event(s) related to the investigational product, an unstable medical condition, or any other reason, in the opinion of the investigator, would preclude entry or participation in this study.
* Subjects who are taking any dose of Azathioprine (AZA), 6-mercaptopurine(6 MP) or Methotrexate (MTX).
Minimum Eligible Age

18 Years

Maximum Eligible Age

66 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Shire

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Shire Director

Role: STUDY_DIRECTOR

Takeda

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Mayo Clinic Arizona - Scottsdale

Scottsdale, Arizona, United States

Site Status

UCSD Altman Clinical and Translational Research Institute

La Jolla, California, United States

Site Status

Community Clinical Trials

Orange, California, United States

Site Status

Rocky Mountain Gastroenterology

Thornton, Colorado, United States

Site Status

Medical Research Center of Connecticut, LLC

Hamden, Connecticut, United States

Site Status

Nature Coast Clinical Research

Inverness, Florida, United States

Site Status

Bassan and Bloom M.D.s

Miramar, Florida, United States

Site Status

Internal Medicine Specialists

Orlando, Florida, United States

Site Status

Shafran Gastroenterology Center

Winter Park, Florida, United States

Site Status

Atlanta Gastroenterology Specialists, PC

Suwanee, Georgia, United States

Site Status

University of Kentucky Medical Center

Lexington, Kentucky, United States

Site Status

Commonwealth Clinical Studies

Brockton, Massachusetts, United States

Site Status

University of Michigan

Ann Arbor, Michigan, United States

Site Status

Minnesota Gastroenterology, PA

Plymouth, Minnesota, United States

Site Status

Center for Digestive and Liver Diseases

Mexico, Missouri, United States

Site Status

Washington University School of Medicine

St Louis, Missouri, United States

Site Status

University of Nevada School of Medicine

Las Vegas, Nevada, United States

Site Status

Dartmouth Hitchcock Medical Center

Lebanon, New Hampshire, United States

Site Status

Albany Medical College

Albany, New York, United States

Site Status

Weill Cornell Medical College of Cornell University

New York, New York, United States

Site Status

Premier Medical Group of the Hudson Valley, PC

Poughkeepsie, New York, United States

Site Status

UNC Memorial Hospital

Chapel Hill, North Carolina, United States

Site Status

The Oregon Clinic-West Hills Gastroenterology Associates, P.C.

Portland, Oregon, United States

Site Status

Gastro One

Germantown, Tennessee, United States

Site Status

Vanderbilt University Medical Center

Nashville, Tennessee, United States

Site Status

Baylor College Of Medicine - Baylor Medical Center

Houston, Texas, United States

Site Status

McGuire DVAMC

Richmond, Virginia, United States

Site Status

Univeristy of Washington

Seattle, Washington, United States

Site Status

Allegiance Research Specialists

Wauwatosa, Wisconsin, United States

Site Status

The Canberra Hospital

Garran, Australian Capital Territory, Australia

Site Status

Concord Repatriation General Hospital

Concord, New South Wales, Australia

Site Status

Royal Brisbane and Women's Hospital

Herston, Queensland, Australia

Site Status

Mater Health Services

South Brisbane, Queensland, Australia

Site Status

Alfred Hospital

Melbourne, Victoria, Australia

Site Status

The Royal Melbourne Hospital

Parkville, Victoria, Australia

Site Status

AKH Wien, Universitaetsklinik fuer Innere Medizin III

Vienna, , Austria

Site Status

AZ St. Elisabeth Herentals

Herentals, , Belgium

Site Status

University Hospital Gasthuisberg

Leuven, , Belgium

Site Status

Centre Hospitalier de Mouscron

Mouscron, , Belgium

Site Status

MBAL Sveti Ivan Rilski, Klinika po Gastroenterologia

Sofia, , Bulgaria

Site Status

(G.I.R.I.) GI Research Institute

Vancouver, British Columbia, Canada

Site Status

Percuro Clinical Research, Ltd

Victoria, British Columbia, Canada

Site Status

Hamilton Health Sciences Corp, McMaster Univ Medical Centre

Hamilton, Ontario, Canada

Site Status

London Health Sciences Centre - University Hospital

London, Ontario, Canada

Site Status

Taunton Surgical Centre

Oshawa, Ontario, Canada

Site Status

Universite de Montreal - Hopital Maisonneuve-Rosemont (HMR)

Montreal, Quebec, Canada

Site Status

Royal University Hospital

Saskatoon, Saskatchewan, Canada

Site Status

Hepato-Gastroenterologie HK s.r.o. Poliklinika III

Hradec Králové, , Czechia

Site Status

IBD Clinical and Research Centre

Prague, , Czechia

Site Status

Krajska zdravotni, a.s., Masarykova nemocnice v Usti nad Labem

Ústí nad Labem, , Czechia

Site Status

CHU Amiens-Picardie - Hopital Sud

Amiens, , France

Site Status

Centre Hospitalier Universitaire (CHU) de Caen - Hopital Cote de Nacre

Caen, , France

Site Status

Hopital Huriez CHRU de Lille

Lille, , France

Site Status

CHU De Nice Hopital De L'Archet II

Nice, , France

Site Status

CHU de Saint-Etienne Hopital Nord

Saint-Priest-en-Jarez, , France

Site Status

CHU de Nancy - Hopital Brabois

Vandœuvre-lès-Nancy, , France

Site Status

Universitaetsklinikum Schleswig-Holstein, Campus Kiel

Kiel, Schleswig-Holstein, Germany

Site Status

Universitaetsklinikum Regensburg, Klinik und Poliklinik fuer Innere Medizin 1

Regensburg, , Germany

Site Status

Csongrad Megyei Dr. Bugyi Istvan Korhaz

Szentes, Csongrád megye, Hungary

Site Status

Shaare Zedek Medical Center

Jerusalem, , Israel

Site Status

Hadassah Ein Kerem University Hospital - Gastroenterology and Liver Diseases Unit

Jerusalem, , Israel

Site Status

Meir Medical Center

Kfar Saba, , Israel

Site Status

The Chaim Sheba Medical Center

Tel Litwinsky, , Israel

Site Status

Universita' degli Studi "Magna Graecia" di Catanzaro

Catanzaro, , Italy

Site Status

Milan University, Humanitas Clinical Institute

Milan, , Italy

Site Status

Policlinico Universitario Campus Bio-Medico

Roma, , Italy

Site Status

Azienda Ospedaliera Universitaria, Policlinico Tor Vergata

Roma, , Italy

Site Status

Azienda Ospedaliera San Camillo Forlanini

Roma, , Italy

Site Status

Universita Cattolica del Sacro Cuore

Roma, , Italy

Site Status

Ospedale Casa Sollievo della Sofferenza

San Giovanni Rotondo, , Italy

Site Status

Academic Medical Center

Amsterdam, , Netherlands

Site Status

University Medical Center Groningen (UMCG)

Groningen, , Netherlands

Site Status

Maastricht University Medical Center

Maastricht, , Netherlands

Site Status

Christchurch Hospital

Christchurch, Canterbury, New Zealand

Site Status

Waikato Hospital

Hamilton, , New Zealand

Site Status

Centrum Endoskopii Zabiegowej

Bydgoszcz, Kuyavian-Pomeranian Voivodeship, Poland

Site Status

Centrum Medyczne-Szpital Swietej Rodziny Sp.z.o.o.

Lodz, Wojlodzkie, Poland

Site Status

Gabinet Endoskopii Przewodu Pokarmowego

Krakow, , Poland

Site Status

NZOZ Centrum Medyczne HCP sp. z o.o

Poznan, , Poland

Site Status

Klinika Chorob Wewnetrznych I Gastroenterologii

Warsaw, , Poland

Site Status

Niepubliczny Zaklad Opieki Zdrowotnej VIVAMED

Warsaw, , Poland

Site Status

Lexmedica

Wroclaw, , Poland

Site Status

St. Petersburg State Medical Academy for Postgraduate Education

Saint Petersburg, , Russia

Site Status

Military Medical Academy

Belgrade, , Serbia

Site Status

Clinical Hospital Center Zemun

Belgrade, , Serbia

Site Status

Clinical Hospital Centre Bezanijska Kosa

Belgrade, , Serbia

Site Status

Ustredna vojenska nemocnica SNP Ruzomberok - Fakultna nemocnica

Nitra, , Slovakia

Site Status

Gastro L., s.r.o.

Prešov, , Slovakia

Site Status

Ustredna vojenska nemocnice SNP Ruzomberok - Fakultna nemocnica

Ružomberok, , Slovakia

Site Status

Kingsbury Hospital

Claremont, Cape Town, South Africa

Site Status

Yeungnam University Medical Center

Daegu, , South Korea

Site Status

Seoul National University Hospital

Seoul, , South Korea

Site Status

Kangbuk Samsung Hospital

Seoul, , South Korea

Site Status

Asan Medical Center

Seoul, , South Korea

Site Status

Samsung Medical Center

Seoul, , South Korea

Site Status

Hospital Universitario Puerta de Hierro

Majadahonda, Madrid, Spain

Site Status

Centro Medico Teknon-Institut de la Macula i de la Retina

Barcelona, , Spain

Site Status

Hospital Clinic de Barcelona

Barcelona, , Spain

Site Status

Parc de Salut Mar-Hospital del Mar

Barcelona, , Spain

Site Status

Countries

Review the countries where the study has at least one active or historical site.

United States Australia Austria Belgium Bulgaria Canada Czechia France Germany Hungary Israel Italy Netherlands New Zealand Poland Russia Serbia Slovakia South Africa South Korea Spain

Provided Documents

Download supplemental materials such as informed consent forms, study protocols, or participant manuals.

Document Type: Study Protocol

View Document

Document Type: Statistical Analysis Plan

View Document

Related Links

Access external resources that provide additional context or updates about the study.

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

2012-002031-28

Identifier Type: EUDRACT_NUMBER

Identifier Source: secondary_id

TURANDOT II

Identifier Type: OTHER

Identifier Source: secondary_id

A7281010

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.